Journal article
Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Abstract
BACKGROUND AND OBJECTIVE: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects.
METHODS: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis who had shown progression of …
Authors
Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB
Journal
Respirology, Vol. 28, No. 5, pp. 465–474
Publisher
Wiley
Publication Date
5 2023
DOI
10.1111/resp.14452
ISSN
1323-7799